Elevance Health Q2 2024 Adj EPS $10.12 Beats $10.01 Estimate, Sales $43.223B Beat $43.054B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elevance Health reported Q2 2024 adjusted EPS of $10.12, beating the estimate of $10.01. Sales were $43.223 billion, also surpassing the estimate of $43.054 billion.
July 17, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevance Health's Q2 2024 earnings and sales both exceeded analyst expectations, with an adjusted EPS of $10.12 beating the $10.01 estimate and sales of $43.223 billion surpassing the $43.054 billion estimate.
The better-than-expected earnings and sales figures are likely to positively impact Elevance Health's stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100